Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 25 25 versus HYDROPANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 25 25 versus HYDROPANE.
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25 vs HYDROPANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting arteriolar vasodilator that reduces peripheral resistance through relaxation of vascular smooth muscle, likely via nitric oxide-mediated increases in cGMP. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption and decreasing plasma volume.
Thiazide diuretic; inhibits sodium chloride cotransporter in distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
One tablet orally twice daily, titrated based on blood pressure response; maximum dose: one tablet four times daily.
50–100 mg orally once daily, maximum 200 mg daily
None Documented
None Documented
Hydralazine: 2-8 hours (terminal half-life; prolonged in renal impairment; acetylator phenotype affects clearance); Hydrochlorothiazide: 6-15 hours (terminal half-life; increased in renal impairment).
Terminal elimination half-life is approximately 8-15 hours in patients with normal renal function; may be prolonged in renal impairment.
Hydralazine: 80% renal (as metabolites, 5-10% unchanged); Hydrochlorothiazide: 95% renal (as unchanged drug).
Renal (approximately 50% as unchanged drug) and hepatic metabolism to inactive metabolites; fecal elimination accounts for about 10%.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic